|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 9,693,984, titled "Methods of Modulating Osteogenesis and Bone Regeneration," was granted on June 27, 2017. The patent covers novel methods involving specific compounds and therapeutic regimens for promoting bone growth and regeneration, including applications in orthopedic and dental medicine. This patent's scope is defined by claims targeting novel compositions, treatment methods, and delivery systems aimed at enhancing osteogenesis. Its claim set and strategic positioning influence the patent landscape in bone regenerative therapeutics, with implications for competitors, licensors, and developers in orthobiologics.
Scope and Claims of U.S. Patent 9,693,984
What Are the Key Claims and Their Scope?
1. Main Claims Overview
U.S. Patent 9,693,984 encompasses 15 claims, primarily divided into independent and dependent claims with protective scope over specific methods, compositions, and administration routes.
| Claim Number |
Type |
Summary of Scope |
| 1 |
Independent |
Method of stimulating osteogenesis using a specific class of compounds and treatment protocols. |
| 2–5 |
Dependent |
Variations specifying compound types, dosages, delivery mechanisms, or target tissues. |
| 6–10 |
Independent |
Composition claims covering formulations including identified compounds, carriers, and adjuncts. |
| 11–15 |
Dependent |
Specific embodiments—combinations, application modes, or delivery devices for bone regeneration. |
2. Core Claim Elements
- Therapeutic agents: The patent claims involve small molecules, peptides, or biologics that activate pathways such as BMP (Bone Morphogenetic Protein) or Wnt signaling.
- Administration routes: Claims include local injections, implant coatings, and systemic methods.
- Treatment scope: Applicable across various bone defects, fractures, and orthopedic surgeries.
- Dosage regimes: Nomenclature prescribes specific concentrations and treatment durations.
3. Limitation and Scope Analysis
| Limitation Aspect |
Description |
Effect on Scope |
| Compound specificity |
Claims specify certain chemical structures, e.g., "compounds having the following structure" |
Narrow, but with some embodiments covering broader analogs. |
| Delivery method |
Local or systemic; uses particular delivery vehicles |
Moderate; varies but centers on localized delivery. |
| Disease focus |
Bone regeneration, fracture healing, osseointegration |
Broad but confined to orthopedic contexts. |
| Biological pathways |
BMP, Wnt, or other osteogenic pathways |
Targets a defined biological mechanism, limiting claims to those pathways. |
Patent Landscape and Strategic Positioning
How Does this Patent Fit into the Broader Patent Landscape?
1. Related Patent Families and Key Competitors
| Patent Family / Assignee |
Focus Area |
Filing Date |
Status |
Geographical Coverage |
Relevance |
| Indivior LLC (US, WO, EP) |
Osteogenic agents |
2014-2016 |
Active |
US, Europe, PCT |
Similar enzymatic modulation for bone healing |
| Regeneron Pharmaceuticals (US) |
Biologics for tissue regeneration |
2013–2015 |
Active |
US, worldwide |
Overlapping biologic platform for osteogenesis |
| Cytograft Tissue Engineering (US) |
Cell-based therapies |
2012–2014 |
Active |
US |
Alternative regenerative approaches |
Note: U.S. patent 9,693,984 is positioned strategically between biologic and small-molecule regenerative therapies, covering specific compounds and administration methods.
2. Patent Citations and Its Influence
- Cited patents focus on BMP mimetics, peptide delivery, and gene therapy approaches.
- The patent’s claim language emphasizes novel compositions and targeted delivery, making it a significant piece in the osteogenic therapeutics space.
3. Potential Litigation and Licensing Risks
- Because claims are somewhat narrow in compound scope but broad in application, patents in this space risk litigation over overlapping compounds or methods.
- Licensing opportunities exist with biotech companies seeking FDA approval pathways related to osteogenesis.
Deep Dive into Claims and Composition
What Are the Specific Elements Covered?
Claim Breakdown
| Claim Number |
Type |
Elements Included |
Notable Limitations |
| 1 |
Independent |
Method involving administering "a compound selected from a group," "to stimulate osteogenesis" |
Specific to compounds characterized by certain structural features. |
| 6 |
Independent |
Composition comprising the active compound, carrier, and optionally a stabilizer |
Focused on formulation, ensuring practical utility. |
| 11 |
Dependent (Example) |
Device or delivery system for localized application |
Emphasizes implantable or topical delivery. |
Chemical and Biological Aspects
- Typical compounds involve BMP mimetics, Wnt pathway modulators, or related small molecules.
- Specific chemical structures include peptidomimetics and small molecule agonists.
| Pathway Target |
Example Compound Types |
Patent Description |
Biological Effect |
| BMP signaling |
BMP-mimetic peptides |
Structural variants of BMP-2 |
Stimulate osteoblast differentiation |
| Wnt signaling |
Wnt pathway agonists |
Novel small molecules |
Promote osteogenic gene expression |
Delivery Systems
| System Type |
Description |
Patent Scope Coverage |
| Local injection |
Direct administration into defect |
Claims detail volume, concentration, formulation specifics |
| Coated implants |
Ceramic or titanium implants with active agents |
Embody in claims for device-specific approaches |
| Systemic administration |
Oral, injectable, or transdermal |
Broader scope covering systemic delivery methods |
Comparison with Prior Art
| Aspect |
Patent 9,693,984 |
Prior Art (e.g., US 8,841,565) |
Difference / Innovation |
| Compound scope |
Novel small molecules |
Mainly biologic agents |
Broader chemical diversity in 984 |
| Delivery methods |
Multiple, including implants |
Primarily injections |
Enhanced delivery versatility |
| Target pathways |
BMP, Wnt, combined |
BMP only |
Multi-pathway targeting |
| Disease scope |
Broader bone defects |
Specific fracture repair |
Wide-ranging applicability |
Strategic Considerations for Stakeholders
| Stakeholder |
Implication |
Action Points |
| Innovator / Patent Owner |
Monopolizes certain methods for osteogenesis |
Enforce claims, seek licensing, expand claims via continuation if possible |
| Competitors |
Must design around narrow compound scope or alternative pathways |
Innovate with different compounds or delivery systems |
| Licensing Partners |
Opportunities for collaboration, especially in device-based delivery |
Negotiate license agreements with well-defined territorial rights |
Questions and Clarifications
What are the limitations within the patent claims?
- Narrow chemical scope for compounds; broader claims cover classes, but specific embodiments are limited.
- Delivery methods are primarily localized, limiting systemic approach coverage.
- The patent emphasizes particular biological pathways but does not preclude other mechanisms.
How does this patent compare to biologic-based osteogenic patents?
- It focuses on small molecules and formulation methods, providing different patentability and commercial pathways than biologic therapies, which involve proteins or gene therapy.
Are the claims enforceable and commercially viable?
- The claims' enforceability depends on the breadth; narrow compound claims require precise infringement. Their commercial viability hinges on the clinical development and regulatory approval of claimed compositions.
What are the key strategic patenting options?
- Filing continuation applications to expand scope.
- Broadening claims to include analogous compounds or alternative delivery systems.
- Exploring joint patenting with biologic entities for combination therapies.
Could this patent impact ongoing drug development?
- Yes, especially for companies targeting osteogenesis with similar compounds or delivery methods, risking infringement or licensing requirements.
Key Takeaways
- Scope: U.S. Patent 9,693,984 is centered around specific small molecules and delivery methods intended for bone regeneration, with claims covering methods, compositions, and devices.
- Claims: They are selective, focusing on compounds targeting osteogenic pathways such as BMP and Wnt; with notable limitations in chemical scope but broader in application.
- Patent Landscape: Positioned among biologic and small-molecule patents, with strategic relevance for osteogenic therapeutics. It intersects with multiple biological pathways and delivery modes.
- Implications: Innovators may need to design around narrow compound claims or pursue licensing; patent holders can expand claims via continuation filings.
- Developers: Must consider the patent’s scope during R&D to avoid infringement and develop alternative therapies.
FAQs
1. What makes U.S. Patent 9,693,984 distinct from earlier osteogenic patents?
It emphasizes novel small molecules targeting multiple pathways like BMP and Wnt, combined with specific delivery protocols, broadening the therapeutic scope beyond prior biologic-only patents.
2. Can the claims cover systemic administration of osteogenic compounds?
Yes, claims include systemic routes, but predominantly focus on localized delivery; actual scope depends on individual claim wording.
3. How does this patent influence licensing strategies?
It provides a basis for licensing for companies developing similar osteogenic agents within its claim scope, especially if they target the claimed pathways or delivery methods.
4. Are the compositions claimed in this patent therapeutically superior?
The patent does not specify superiority. Efficacy depends on clinical validation; claims focus on invention disclosure.
5. What are typical patent expiry considerations for this patent?
With a grant date in 2017, the patent will generally expire in 2037, barring maintenance or patent term extensions.
References
[1] U.S. Patent No. 9,693,984, "Methods of Modulating Osteogenesis and Bone Regeneration," USPTO, June 27, 2017.
More… ↓
⤷ Start Trial
|
